rmdopen.bmj4h
Forefoot inflammation in recent-onset ACPA-positive and ACPA-negative RA: clinically similar, but different in underlying inflamed tissues
Objectives Although joint swelling is traditionally interpreted as synovitis, recent imaging studies showed that there is also inflammation of tenosynovium and intermetatarsal bursae in the forefoot.
rmdopen.bmj3d
On difficulties to define prognostic factors for clinical practice in rheumatoid arthritis
In rheumatoid arthritis (RA), the identification of prognostic factors (PF) capable of predicting disease outcome, response ...
rmdopen.bmj7d
Earlier is better when treating rheumatoid arthritis: but can we detect a window of opportunity?
Objectives The window of opportunity (WOO) hypothesis suggests a limited time frame to stop rheumatoid arthritis (RA). We hypothesised that a WOO could either be represented by a hyperbolic (‘curved’) ...
rmdopen.bmj8d
Genes deregulated in giant cell arteritis by Nanostring nCounter gene expression profiling in temporal artery biopsies
Objective To identify differentially expressed genes in temporal artery biopsies (TABs) from patients with giant cell arteritis (GCA) with different histological patterns of inflammation: transmural ...
rmdopen.bmj9d
Frailty is independently associated with subclinical cardiovascular disease in patients with systemic lupus erythematosus
Objectives Cardiovascular disease is a leading cause of mortality in systemic lupus erythematosus (SLE). Frailty has been ...
rmdopen.bmj11d
Comparative early effectiveness across 14 PsA drugs and 5 classes of PsA treatment: 3-month results from the PRO-SPIRIT study
Background The psoriatic arthritis (PsA) Observational Study of Persistence of Treatment (PRO-SPIRIT) assesses effectiveness and persistence of real-world PsA treatments. Ixekizumab (IXE) is an ...
rmdopen.bmj12d
Efficacy and safety of filgotinib in methotrexate-naive patients with rheumatoid arthritis with poor prognostic factors: post hoc analysis of FINCH 3
Objective This analysis evaluated efficacy and safety of filgotinib, a Janus-associated kinase 1-preferential inhibitor, in methotrexate (MTX)-naive patients with rheumatoid arthritis (RA) with ...
rmdopen.bmj13d
Prediction of progressive fibrosing interstitial lung disease in patients with systemic sclerosis: insight from the CRDC cohort study
Background This study aims to establish a reliable prediction model of progressive fibrosing interstitial lung disease (PF-ILD) in patients with systemic sclerosis (SSc)-ILD, to achieve early risk ...
rmdopen.bmj15d
Cigarette smoking patterns preceding primary Sjögren’s syndrome
Background Cigarette smoking is a well-established risk factor for several autoimmune diseases, but its role in primary Sjögren’s syndrome (pSS) remains unclear. Here, we investigated the association ...
rmdopen.bmj18d
Impact of filgotinib on pain control in the phase 3 FINCH studies
Present affiliation The present affiliation of Shangbang Rao is: Candel Therapeutics, Needham, MA, USA Present affiliation The present affiliation of Pieter-Jan Stiers is: AgomAb Therapeutics, Ghent, ...
rmdopen.bmj1mon
Early prediction of treatment response in rheumatoid arthritis by quantitative macrophage PET
Correspondence to Dr Conny van der Laken; j.vanderlaken{at}amsterdamumc.nl Conclusion Quantitative macrophage PET assessment of feet joints, together with DAS44, after 2 weeks of COBRA light treatment ...